# Revelation Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revelation-biosciences

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.revbiosciences.com
- Total disclosed funding: $4M
- Latest round: Series A (Jan 5, 2021)
- Investors on record: 1

## About

Revelation Biosciences, Inc. is focused on developing therapeutic solutions that modulate the immune response to improve health outcomes, primarily through their innovative product, Gemini.Founded in 2020 in San Diego, US, Revelation Biosciences, Inc. specializes in creating immune-modulating therapies. The company underwent a merger with Petra Acquisition Inc. in December 2021, leading to its forthcoming public listing. The CEO, James Rolke, oversees operations and strategic direction. As of July 2022, the company raised USD 5 mn through a Private Placement/Follow on round, with the total amount raised reaching USD 15.6 mn.Revelation Biosciences develops therapeutic solutions to address inflammation-related health issues. Their primary product, Gemini, is an intravenous formulation designed to modulate the innate immune response in patients facing trauma and infection. The target market includes healthcare providers and institutions across North America, Europe, and Asia, aiming to support patients in critical care settings.Revenue for Revelation Biosciences is generated through direct sales of Gemini to healthcare providers, based on B2B agreements with hospitals and clinics. Pricing strategies are customized to meet institutional contract requirements, fostering long-term partnerships to ensure consistent supply and revenue stability.Revelation Biosciences plans to leverage its most recent funding to enhance product development and market expansion. The company is working on new products aimed at further optimizing its therapeutic offerings. Additionally, they seek to broaden their market reach, focusing on North America, Europe, and Asia by the end of 2024. The recent funding, which includes USD 5 mn raised in July 2022, will support these initiatives, particularly the upcoming product launches and expansion efforts.

## Funding rounds

- Series A, Jan 5, 2021, $4M — Global Health Impact Funds

## Investors

- Global Health Impact Funds (https://capitalatlas.ai/funds/global-health-impact-funds) — Series A